Bicycle Therapeutics PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team with the third day of our 5th Annual HealthCONx Healthcare Conference. I've been looking forward to this session for -- since this -- for a long time. Pleased to introduce from Bicycle Therapeutics, we have Kevin Lee, Chief Executive Officer; Lee Kalowski, President and Chief Financial Officer; Nick Keen, Chief Scientific Officer; Dominic Smethurst, Chief Medical Officer; and Dave Borah, Vice President of Capital Markets and Investor Relations. So welcome to the Bicycle team.
I'm going to kick things off with kind of a leading question. We've talked a lot about ADC constructs and what -- they really do target chemo to the tumor or tumor acting as kind of like a depo effect for systemic chemo release, which itself is actually very powerful and very effective. Like so on the one end, then there's this concept that maybe ADCs or antibodies plus chemo, it just kind of connected in a certain way.
There's another end of the spectrum, though, where the agencies aren't necessarily
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
